Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 36Breast Neoplasms 29Pancreatic Neoplasms 20Rectal Neoplasms 17Stomach Neoplasms 16Neoplasm Metastasis 16Neoplasms 12Esophageal Neoplasms 8Triple Negative Breast Neoplasms 7Colonic Neoplasms 7Colorectal Cancer Metastatic 6Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Brain Neoplasms 4Adenocarcinoma 4Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Biliary Tract Neoplasms 3Bile Duct Neoplasms 3Advanced Solid Tumors 3Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Diabetes Mellitus, Insulin-Dependent, 12 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2

Interventions

Trastuzumab 3Paclitaxel 3Docetaxel 3Taxes 2Cyclophosphamide 2trastuzumab biosimilar HLX02 1tipifarnib 1romidepsin 1pertuzumab 1pegfilgrastim 1onvansertib 1neratinib 1grapiprant 1eribulin 1caficrestat 1Peripheral Blood Stem Cell Transplantation 1PF-05280014 1Ontruzant 1Ogivri 1Mesna 1Lapatinib 1Filgrastim 1Epirubicin 1Doxorubicin 1Depsipeptides 1Carboplatin 1Capecitabine 1Albumin-Bound Paclitaxel 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Inflammatory Breast Neoplasms × Capecitabine × Clear all
NCT00070252 2015-05-04

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
53 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡